The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Fixed-duration or MRD-adapted therapy in CLL: insights from ASH 2025
In this video, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses impactful data from ASH 2025 in the field of chronic lymphocytic leukemia (CLL), mentioning trials investigating fixed-duration or measurable residual disease (MRD)-adapted therapy. Dr Davids highlights that these two approaches to treatment have not yet been directly compared, and looks forward to future meetings at which trials comparing these strategies will be presented. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
